As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales ...

Leading data and analytics company GlobalData’s report, Human Immunodeficiency Virus (HIV): Seven-Market Drug Forecast, ...

When investing in dividend stocks, paying attention to the right things is essential. A high yield can be attractive, but the ...

Metformin use in patients with HIV and type 2 diabetes who had at least 2 years of exposure to effective ART showed no significant effect on immune reconstitution.

In the hunt for a remedy, when the baton is passed from dedicated academic scientists to an innovative company to trusted community advocates, outcomes for society can be especially powerful.

Storm clouds hung low above a community center in Jackson, where pastor Andre Devine invited people inside for lunch. Hoagies ...

Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US, adding $11 billion in ...

President Trump has eliminated funding for programs aimed at ending the growing HIV epidemic among minority communities, ...

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we ...

The Gilead team wanted to see if they could use Sundquist's insights about how to hinder viral replication to design HIV drugs with longer acting power for people living with HIV; while the ...

After counsel withdrew for some of the plaintiffs in a huge consolidated legal battle between Gilead Sciences and patients ...